Nu-Med Plus (NUMD) Net Cash Flow Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) Net Cash Flow Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.33 Bn | 174.04 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 128.11 Bn | 125.23 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 107.76 Bn | 98.54 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 67.95 Bn | 66.50 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | -564.44% |
| 6 | GE HealthCare Technologies | 28.43 Bn | 26.14 Bn | 1.98 Bn | -394.13% |
| 7 | Dexcom | 28.31 Bn | 27.20 Bn | 750.30 Mn | -31.84% |
| 8 | Smith & Nephew | 26.77 Bn | 26.19 Bn | - | - |
| 9 | Koninklijke Philips | 25.33 Bn | 22.21 Bn | 2.07 Bn | 76.43% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | 22.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.84% |
| Dec 31, 2024 | 61.05% |
| Jun 30, 2024 | 89.97% |
| Mar 31, 2024 | 97.77% |
| Dec 31, 2023 | 82.47% |
| Sep 30, 2023 | -3,104.62% |
| Jun 30, 2023 | -809.42% |
| Mar 31, 2023 | -120.68% |
| Dec 31, 2022 | -21.17% |
| Sep 30, 2022 | 101.53% |
| Jun 30, 2022 | 96.18% |
| Mar 31, 2022 | 81.44% |
| Dec 31, 2021 | -112.84% |
| Sep 30, 2021 | -261.43% |
| Jun 30, 2021 | -443.56% |
| Mar 31, 2021 | -537.74% |
| Dec 31, 2020 | 551.70% |
| Sep 30, 2020 | -2.91% |
| Jun 30, 2020 | -61.03% |
| Mar 31, 2020 | 107.80% |